Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 10/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12107659 | 0.93 | METTL3 (0.49) | METTL3EGFRKCNJ5KCNJ3CXCR2 | |
| SCHEMBL1300623 | 0.89 | METTL3 (0.72) | METTL3EGFRTP53POLBRXFP1 | |
| SCHEMBL1300242 | 0.89 | METTL3 (0.72) | METTL3EGFRTP53POLBRXFP1 | |
| SCHEMBL12107926 | 0.89 | METTL3 (0.72) | METTL3EGFRTP53POLBRXFP1 | |
| SCHEMBL12107653 | 0.89 | METTL3 (0.46) | METTL3EGFRKCNJ5KCNJ3P2RX7 | |
| SCHEMBL12107831 | 0.89 | METTL3 (0.62) | METTL3EGFRTP53POLBRXFP1 | |
| SCHEMBL13771368 | 0.89 | METTL3 (0.62) | METTL3EGFR | |
| SCHEMBL12107662 | 0.88 | METTL3 (0.46) | METTL3EGFRKCNJ5KCNJ3CXCR2 | |
| SCHEMBL12108080 | 0.85 | METTL3 (0.60) | METTL3 | |
| SCHEMBL12107670 | 0.85 | METTL3 (0.42) | METTL3EGFRCXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885EGFR 4552/4885KCNJ5 4207/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885EGFR 4552/4885KCNJ5 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.